Levofloxacin prophylaxis in patients with myeloma
Benjamin W Teh, Simon J Harrison, Leon J Worth, Karin A Thursky, Monica A Slavin
The Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2020
BWT has received grant funding from Merck Sharpe and Dohme (MSD), Sanofi-Pasteur; and has received speaker fees from Gilead Sciences. SJH has received research funding from Celgene/Bristol Myers Squibb (BMS), Janssen-Cilag, Novartis, Amgen, Haemalogix, and Abbvie; is on the advisory board of Celgene/BMS, Janssen-Cilag, Novartis, Amgen, Haemalogix, Abbvie, and Takeda; and has received honoraria for presentations from Takeda. MAS has been on Antifungal Advisory Boards of Gilead Sciences, MSD, Pfizer, and F2G; and has received untied grants from Gilead Sciences and MSD and honoraria for presentations from Pfizer, Gilead Sciences, and MSD. All other authors declare no competing interests.